Clinical trials: Progressive Low-Grade Glioma
Low-grade Glioma
Vinorelbine for Children With Progressive or Recurrent Low-grade Gliomas
The purpose of this study is to investigate whether weekly Vinorelbine treatment can shrink or slow the growth of pediatric low-grade gliomas that have either returned or are continuing to grow.
- Trial name
- NCT01497860
- Testing
- Vinorelbine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Eugene Hwang
Low-Grade Astrocytoma, Nos
Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma
RATIONALE: Current therapies for adult recurrent/progressive low grade astrocytoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment…
- Trial name
- NCT00003471
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Burzynski Research Institute
Pediatric Recurrent Progressive Low-grade Gliomas, Pediatric Progressive Low-grade Gliomas
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.
- Trial name
- NCT01734512
- Testing
- Everolimus
- Where
- 18 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of California, San Francisco
Glioma
Everolimus for Children With NF1 Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas in children with Neurofibromatosis type 1 (NF1). Additionally, the safety of RAD001 will be studied.
- Trial name
- NFC-RAD001 (NCT01158651)
- Testing
- RAD001 (Everolimus)
- Where
- 12 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Gliomas
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
The objective of this study is to determine response rates (partial and complete responses) to nivolumab of recurrent or progressive IDH mutant (grades 2, 3 or 4) gliomas with prior exposure to alkylating agents.
- Trial name
- NCT03557359
- Testing
- Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Fabio Iwamoto, MD
Glioma, Low-grade Glioma
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas
The purpose of this research study is to learn if the study drug RAD001 can shrink or slow the growth of low-grade gliomas. Additionally, the safety of RAD001 will be studied.
- Conditions
- Glioma, Low-grade Glioma, Astrocytoma
- Trial name
- NCT00782626
- Testing
- everolimus
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
This phase II trial is studying how well giving bevacizumab together with irinotecan works in treating young patients with recurrent, progressive, or refractory glioma, medulloblastoma, ependymoma, or low grade glioma.
- Conditions
- Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma
- Trial name
- NCT00381797
- Testing
- Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Central Nervous System Tumor
Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as carboplatin, vincristine, and temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00077207
- Testing
- carboplatin, temozolomide, vincristine sulfate
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Children's Oncology Group
NF1, Low-grade Glioma
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1.
- Trial name
- NF111 (NCT04544007)
- Testing
- Poly ICLC
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG)
Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas
The purpose of this study is to determine if a drug called sorafenib can shrink LGA tumors (low-grade astrocytomas) in children and adults.
- Conditions
- neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
- Trial name
- NCT01338857
- Testing
- Sorafenib (Nexavar)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- NYU Langone Health
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc